NIH Awards The Texas Heart Institute $1.14 Million to Develop a Novel, First-in-Class Drug for Atherosclerotic Cardiovascular Disease (IMAGE)

Texas Heart Institute

NIH Awards The Texas Heart Institute $1.14 Million to Develop a Novel, First-in-Class Drug for Atherosclerotic Cardiovascular Disease

Caption

Dr. Ronald J. Biediger, Director of Medicinal Chemistry, and Dr. Darren G. Woodside, Vice President for Research, Senior Investigator, and Director of the Flow Cytometry and Imaging Core at The Texas Heart Institute (THI).

Credit

© THE TEXAS HEART INSTITUTE 2023

Usage Restrictions

Photo Credit

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.